Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function
BJU International · 2025
DOI: 10.1111/bju.16606 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Eiftu S Haile und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Sarcopenia, Urinary Bladder Neoplasms, Cisplatin, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To assess whether the effect of sarcopenia on neoadjuvant chemotherapy (NAC) toxicity is modified by borderline renal function (estimated glomerular filtration rate [eGFR] 40–65 mL/min) and whether sarcopenia and borderline renal function are independently associated with NAC toxicity risk. Patients and Methods All patients with muscle‐invasive bladder cancer (MIBC) who underwent radical cystectomy (RC) between 2010 and 2022, with available cross‐sectional imaging prior to NAC initiation, were included. Skeletal mass was measured from axial computed tomography images obtained at the level of the L3 vertebral body, using Aquarius Intuition software. Sarcopenia was assigned based on consensus definitions of skeletal mass index. NAC toxicity was graded according to Common Terminology Criteria for Adverse Events version 5.0. Binary logistic regression was used to identify the predictors of NAC‐associated renal toxicity.
Results
A total of 216 patients were included. Most patients had sarcopenia (83%) and received gemcitabine/cisplatin NAC (76%). In an unadjusted model, sarcopenia was associated with a significant risk of renal‐associated NAC toxicity (odds ratio [OR] 4.88, 95% confidence interval [CI] 1.65–14.44; P = 0.004). In an effect modification model evaluating the interaction between sarcopenia and renal function, the OR for renal toxicity with sarcopenia among patients with eGFR 40–65 mL/min was 8.46 (95% CI 1.06–67.72) vs 3.11 (95% CI 0.81–11.88) among patients with normal renal function ( P = 0.43).
Conclusion
Among MIBC patients who received NAC, sarcopenia was associated with higher odds of NAC‐associated renal toxicity and may increase risk of renal toxicity among patients with borderline renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
- Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.
- Department of Quantitative Health Science, Cleveland Clinic, Cleveland, OH, USA.
- Department of Kidney Medicine, Cleveland Clinic, Cleveland, OH, USA.
- Department of Medical Oncology, Taussig Cancer Institute, Cleveland, OH, USA.
- Section of Abdominal Imaging, Imaging Institute, Cleveland, OH, USA.
ORCID-Profile: Eiftu S Haile, Andrew Wood, Nima Almassi
Zitieren
APA
Haile, E. S., Lone, Z., Shin, D., Nowacki, A. S., Soputro, N., Harris, K., Campbell, R. A., Wood, A., Haywood, S. C., Eltemamy, M., Haber, G. P., Weight, C. J., Wood, H. M., Taliercio, J. J., Nizam, A., Gupta, S., Remer, E. M., & Almassi, N. (2025). Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function. BJU International. https://doi.org/10.1111/bju.16606
Vancouver
Haile ES, Lone Z, Shin D, Nowacki AS, Soputro N, Harris K, et al. Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function. BJU International. 2025. doi:10.1111/bju.16606
BibTeX
@article{Haile2025,
author = {Haile, Eiftu S and Lone, Zaeem and Shin, David and Nowacki, Amy S and Soputro, Nicolas and Harris, Kyle and Campbell, Rebecca A and Wood, Andrew and Haywood, Samuel C and Eltemamy, Mohamed and Haber, Georges-Pascal and Weight, Christopher J and Wood, Hadley M and Taliercio, Jonathan J and Nizam, Amanda and Gupta, Shilpa and Remer, Erick M and Almassi, Nima},
title = {Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16606}
}
EUVIMED